APA (7th ed.) Citation

J, K., EM, G., V, G., EL, P., RJ, B., M, R., . . . SH, P. (2011). Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer, 117(2), 318. https://doi.org/10.1002/cncr.25374

Chicago Style (17th ed.) Citation

J, Kao, et al. "Phase 2 Trial of Concurrent 5-fluorouracil, Hydroxyurea, Cetuximab, and Hyperfractionated Intensity-modulated Radiation Therapy for Locally Advanced Head and Neck Cancer." Cancer 117, no. 2 (2011): 318. https://doi.org/10.1002/cncr.25374.

MLA (9th ed.) Citation

J, Kao, et al. "Phase 2 Trial of Concurrent 5-fluorouracil, Hydroxyurea, Cetuximab, and Hyperfractionated Intensity-modulated Radiation Therapy for Locally Advanced Head and Neck Cancer." Cancer, vol. 117, no. 2, 2011, p. 318, https://doi.org/10.1002/cncr.25374.